Once a clinical trial has been completed, especially when the trial is positive, researchers will “data mine” the published information. The published results provide additional opportunities to evaluate the data in different ways than the trial was originally designed. This new data can be very interesting and informative, however it also needs to be considered [...]
Researchers are now beginning to understand which men with castration-resistant prostate cancer (CRPC) might be helped by radium-223 (Xofigo), and for which men Xofigo will be a waste of time and money, and possibly cause harm. They have found that baseline ECOG performance status, alkaline phosphatase (ALP), hemoglobin (Hb) levels, and the concomitant use of abiraterone acetate (Zytiga) [...]
Many people consider food diet important in both prostate cancer prevention and in controlling its progression. Dietary derived agents, such as the flavonoids derived from fruits and vegetables should be of particular interest for prostate cancer survivors, as they seem to offer both chemo-prevention and an antioxidant effect along with a favorable safety and side-effect [...]
Believe it or not, in this week approaching Thanksgiving, we in the United States are faced with a second challenge to Prostate Cancer screening using the PSA test. Malecare wants you to know. The Centers for Medicare and Medicaid Services (CMS) is asking for pubic comment on a clinical quality measure that would probably [...]
On October 27, 2015, Malecare was issued patent 9,168,002 for a device and method for real time simultaneous measurement of radiation at specific parts of your body,. Understanding cumulative radiation exposure in people undergoing ionizing radiation for diagnostics and medical treatment is essential towards reducing secondary tumors from primary radiation therapy. We believe that the [...]